Novo Holdings Joins €30M Series A Financing for Asgard Therapeutics, Leader In In Vivo Cell Reprogramming To Treat Cancer
- Financing to advance first platform designed to reprogram cancer cells into immune cells as pan-tumoral cancer treatment
- Novo Holdings participation follows earlier investment and incubation through seed phase
- Financing co-led by RV Invest and Johnson & Johnson Innovation, joined by existing investors Boehringer Ingelheim Venture Fund and Industrifonden
COPENHAGEN – March 14th, 2024 – Novo Holdings, a leading global life sciences investor, today announced its participation in a €30M Series A financing for Asgard Therapeutics, a biotech company pioneering direct in vivo cell reprogramming for cancer immunotherapy. The financing was co-led by RV Invest and Johnson & Johnson Innovation – JJDC, Inc. – with participation from existing investors Novo Holdings, Boehringer Ingelheim Venture Fund and Industrifonden.
